COMMUNIQUÉS West-GlobeNewswire

Avid Bioservices Announces Proposed Private Placement of Convertible Notes
06/03/2024
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, [...]
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
06/03/2024
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
06/03/2024
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidance Fourth Quarter 2023 Net [...]
Supernus to Participate in Two Upcoming Investor Conferences
06/03/2024
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
Pathway Health Launches Learning Institute and Education Advisory Board
06/03/2024
The Pathway Learning Institute will develop evidence-based education and board certification programs to support the development of senior care clinical and operational leaders. LAKE ELMO, Minn., March 06, 2024 (GLOBE [...]
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
06/03/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
06/03/2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
06/03/2024
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on [...]
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
06/03/2024
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for [...]
Nanobiotix to Present at Upcoming Investor Conferences in March
06/03/2024
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
Nanobiotix participera à des conférences investisseurs en mars
06/03/2024
PARIS et CAMBRIDGE, Mass., 06 mars 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06/03/2024
Highlights TTX-MC138’s Path from Target Discovery to the Clinic BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating [...]
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
06/03/2024
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage [...]
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
06/03/2024
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics [...]
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
06/03/2024
BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/03/2024
CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2024
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
06/03/2024
Record full year 2023 revenue of $148.7 million increased 22% compared to prior year WARSAW, Ind., March 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company [...]
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]

Pages